CYP26B1 Antibody

Code CSB-PA006403GA01HU
Size $600
Order now
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Uniprot No.
Target Names
CYP26B1
Alternative Names
CP26 antibody; CP26B_HUMAN antibody; CYP26A2 antibody; cyp26b1 antibody; Cytochrome P450 26A2 antibody; Cytochrome P450 26B1 antibody; Cytochrome P450 family 26 subfamily B polypeptide 1 antibody; Cytochrome P450 retinoic acid-inactivating 2 antibody; Cytochrome P450 retinoid metabolizing protein antibody; Cytochrome P450 subfamily XXVIA; polypeptide 2 antibody; Cytochrome P450 subfamily XXVIB polypeptide 1 antibody; Cytochrome P450RAI-2 antibody; DKFZp686G0638 antibody; dol antibody; EC 1.14. antibody; fc21d03 antibody; MGC129613 antibody; P450 26A2 antibody; P450 retinoic acid inactivating 2 antibody; P450RAI 2 antibody; P450RAI2 antibody; Retinoic acid metabolizing cytochrome antibody; Retinoic acid-metabolizing cytochrome antibody; RHFCA antibody; stocksteif antibody; wu:fc21d03 antibody; wu:fc26h10 antibody; zgc:76999 antibody
Raised in
Rabbit
Species Reactivity
Human,Mouse,Rat
Immunogen
Human CYP26B1
Immunogen Species
Homo sapiens (Human)
Isotype
IgG
Purification Method
Antigen Affinity purified
Concentration
It differs from different batches. Please contact us to confirm it.
Buffer
PBS with 0.02% Sodium Azide, 50% Glycerol, pH 7.3. -20°C, Avoid freeze / thaw cycles.
Tested Applications
ELISA,WB,IHC,IF
Troubleshooting and FAQs
Storage
Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
Lead Time
Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Target Background

Function
Involved in the metabolism of retinoic acid (RA), rendering this classical morphogen inactive through oxidation. Involved in the specific inactivation of all-trans-retinoic acid (all-trans-RA), with a preference for the following substrates: all-trans-RA > 9-cis-RA > 13-cis-RA. Generates several hydroxylated forms of RA, including 4-OH-RA, 4-oxo-RA, and 18-OH-RA. Catalyzes the hydroxylation of carbon hydrogen bonds of atRA primarily at C-4. Essential for postnatal survival. Plays a central role in germ cell development: acts by degrading RA in the developing testis, preventing STRA8 expression, thereby leading to delay of meiosis. Required for the maintenance of the undifferentiated state of male germ cells during embryonic development in Sertoli cells, inducing arrest in G0 phase of the cell cycle and preventing meiotic entry. Plays a role in skeletal development, both at the level of patterning and in the ossification of bone and the establishment of some synovial joints.; Has also a significant activity in oxidation of tazarotenic acid and may therefore metabolize that xenobiotic in vivo.
Gene References into Functions
  1. we provide the third family affected by the disorder and the first affected individual to survive beyond infancy. This woman homozygous for c.1303G>A; p.(Gly435Ser) in CYP26B1, which was associated with multisutural synostosis, radiohumeral synostosis, normal bone mineral density, and apparent intellectual disability, a phenotype with significant similarities to Antley-Bixler and Pfeiffer syndromes. PMID: 27410456
  2. Study investigated the distribution of Cyp26a1 and Cyp26b1 transcripts in the rat and human brain, identifying several novel regions of expression, including the cerebral cortex for both enzymes and striatum for Cyp26b1. PMID: 26374207
  3. Holo-CRABPs had higher affinity for CYP26B1 than free atRA, but both apo-CRABPs(CRABP-I and CRABP-II ) inhibited the formation of 4-OH-RA by CYP26B1. PMID: 27416800
  4. There was increased expression of mRNA CYP26B1 in oral cancer tissue compared to adjacent noncancerous tissues. PMID: 25839051
  5. Our results suggested that the CYP26B1 splice variant is associated with the occurrence of BQ-related oral cancer. PMID: 25114974
  6. homozygous carriers of the major (T) allele, relative to homozygous carriers of the minor (C) allele, of the CYP26B1 polymorphism rs2241057 may have an increased risk for the development of Crohn's disease. PMID: 23977348
  7. inhibits fibroblasts-induced activation of mast cells and dermatitis PMID: 24726878
  8. We report a 2p13.2 microdeletion in 2 subjects encompasing 2 genes, EXOC6B and CYP26B12 with clinical effects on cognitive function, and craniofacial and skeletal development. PMID: 23837398
  9. Single nucleotide polymorphisms in CYP26B1, NANOS1 and STRA8 genes support involvement of meiotic program initiation genes in modifying the risk of azoospermia and oligozoospermia in a Han-Chinese population PMID: 23320086
  10. CYP26B1 capacity is genetically regulated and suggest that local CYP26B1 activity may influence atherosclerosis. PMID: 22415012
  11. Vascular cells express the spliced variant of CYP26B1 lacking exon 2 and it is also increased in atherosclerotic lesions PMID: 22666329
  12. Detection of the methylation prevalence of KCNA4 and CYP26B1 together in serum demonstrated the good sensitivity and specificityin gastric cancer PMID: 21945024
  13. Human null and hypomorphic mutations were identified in the gene encoding the retinoic acid degrading enzyme CYP26B1 that lead to skeletal and craniofacial anomalies, including fusions of long bones, calvarial bone hypoplasia, and craniosynostosis PMID: 22019272
  14. The mRNA expression of CYP26A1 and CYP26B1 correlated between human tissues except for human cerebellum in which CYP26B1 was the predominant CYP26 and liver in which CYP26A1 dominated. PMID: 22020119
  15. The presence of CYP26B1 in normal lung development (A549 cell line), & the capacity to convert retinol to retinoic acid, indicates that fetal human lung has the ability to regulate the supply of vitamin A from the pseudoglandular stage. PMID: 21482329
  16. Increased expression of the CYP26B1 gene was observed in tumor tissue compared with adjacent normal tissue and it plays a novel role in the betel dependent pathogenesis of oral squamous cell carcinoma. PMID: 21641851
  17. role of CYP26 in the regulation of all trans retinoic acid levels in human aortic smooth muscle cells PMID: 20606468
  18. The predominant expression of CYP26A1 in the liver is in agreement with previous reports of tissue distribution of CYP26 mRNA in adult humans. PMID: 19884280
  19. Studies in mice found that regulation of retinoid levels, affected by the retinoid-degrading enzyme CYP26B1, during fetal gonad development determined whether germ cells would become oocytes or spermatogonia. PMID: 16574820
  20. CYP26B1 mRNA levels were approximately twice the level in adult cerebellum compared to adult whole brain samples. CYP26B1 levels were 10x higher in earlier gestational times than in later gestational times. PMID: 12101034
  21. Mouse studies identified different expression patterns of the retinoic acid-metabolizing enzymes CYP26A1 and CYP26B1 during development. PMID: 11744378

Show More

Hide All

Involvement in disease
Radiohumeral fusions with other skeletal and craniofacial anomalies (RHFCA)
Subcellular Location
Endoplasmic reticulum membrane; Peripheral membrane protein. Microsome membrane; Peripheral membrane protein.
Protein Families
Cytochrome P450 family
Tissue Specificity
Highly expressed in brain, particularly in the cerebellum and pons.
Database Links

HGNC: 20581

OMIM: 605207

KEGG: hsa:56603

STRING: 9606.ENSP00000001146

UniGene: Hs.91546

icon of phone
Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
icon of address
Address
7505 Fannin St., Ste 610, Room 7 (CUBIO Innovation Center), Houston, TX 77054, USA
icon of social media
Join us with

Subscribe newsletter

Leave a message

* To protect against spam, please pass the CAPTCHA test below.
CAPTCHA verification
© 2007-2024 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1
Place an order now

I. Product details

*
*
*
*

II. Contact details

*
*

III. Ship To

*
*
*
*
*
*
*

IV. Bill To

*
*
*
*
*
*
*
*